Search research articles
Contact Us
Filters
Showing results (331-340 of 426) with videos related to
Page
of 43
Sort By:
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Sophie Archer, Phillip M Brailey, Minjung Song, et al.
European Urology
|
February 13, 2018
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
Joaquin Mateo, Heather H Cheng, Himisha Beltran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
European Urology
|
September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
Debashis Sarker, Joo Ern Ang, Richard Baird, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Susan Halabi, Qian Yang, Akash Roy, et al.
Page
of 43
Search research articles
Search
Showing results (331-340 of 426) with videos related to
Sort By:
Page
of 43
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Sophie Archer, Phillip M Brailey, Minjung Song, et al.
European Urology
|
February 13, 2018
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
Joaquin Mateo, Heather H Cheng, Himisha Beltran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
European Urology
|
September 2, 2022
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, et al.
European Urology Oncology
|
November 8, 2023
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Evan Y Yu, William R Berry, Howard Gurney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
Debashis Sarker, Joo Ern Ang, Richard Baird, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
Alison H M Reid, Gerhardt Attard, Daniel C Danila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Susan Halabi, Qian Yang, Akash Roy, et al.
Page
of 43